Evoke Pharma (NASDAQ:EVOK) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a research report released on Thursday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Price Performance

NASDAQ:EVOK opened at $4.37 on Thursday. The firm’s fifty day moving average price is $5.15 and its 200 day moving average price is $5.43. Evoke Pharma has a 1-year low of $3.54 and a 1-year high of $17.40. The firm has a market cap of $6.51 million, a price-to-earnings ratio of -0.40 and a beta of 0.36.

Hedge Funds Weigh In On Evoke Pharma

An institutional investor recently bought a new position in Evoke Pharma stock. Corsair Capital Management L.P. acquired a new stake in Evoke Pharma, Inc. (NASDAQ:EVOK) during the third quarter, according to its most recent filing with the SEC. The firm acquired 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned about 1.42% of Evoke Pharma at the end of the most recent reporting period.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.